Cellular changes and antitumor responses in the plasmacytoma-bearing mouse following cyclophosphamide treatment

• Published in: Cancer research (Chicago, Ill.) Vol. 45; no. 12; pp. 6463 - 6470
• Main Authors: SHANAHAN, T. C, CEGLOWSKI, W. S, HAVAS, H. F
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.12.1985
• Subjects: Animals; Antigens, Surface - analysis; Antineoplastic agents; Biological and medical sciences; Carboxylesterase; Carboxylic Ester Hydrolases - metabolism; Chemotherapy; Cyclophosphamide - therapeutic use; Female; Immunity, Cellular; Immunosuppression; Medical sciences; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Pharmacology. Drug treatments; Plasmacytoma - drug therapy; Plasmacytoma - immunology; Plasmacytoma - pathology; Receptors, Antigen, B-Cell - analysis; Spleen - enzymology; Spleen - immunology; Thy-1 Antigens; Antineoplastic agent; Rodentia; Splenocyte; In vitro; Cell surface; In vivo; Vertebrata; Alkylating agent; Chemotherapy; Immunosuppression; Mammalia; Cell population; Mouse; Animal; Models; Plasmacytoma; Experimental tumor; Humoral immunity

Mice bearing the immunosuppressive plasmacytoma TEPC-183 exhibit a marked splenic hyperplasia. We have characterized these tumor-reactive splenocytes on the basis of cell surface marker expression, nonspecific esterase activity, and morphology. Although splenocyte numbers increased progressively thr...